secwatch.observer — SEC 8-K summary
======================================

Issuer:     LivaNova PLC (LIVN)
CIK:        0001639691
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001639691-26-000031
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LivaNova Q1 revenue $362.3M (+14.3% YoY); raises FY2026 guidance; FDA PMA for aura6000 OSA system
--------------------------------------------------------------------------------

- Q1 revenue $362.3M (+14.3% reported, +11.1% CC); GAAP EPS $0.40, adjusted EPS $0.98.
- Raised FY2026 constant-currency revenue growth guidance to 7.0%-8.0% (up 100bps); adjusted EPS guidance raised to $4.20-$4.30.
- Received FDA PMA for aura6000 HGNS system for moderate-to-severe OSA; no CCC contraindication or pre-implant DISE required.
- Published 12-month OSPREY trial results in Annals of Internal Medicine; demonstrated clinically significant responses.
- Q1 adjusted free cash flow $3.8M; maintained FY2026 adjusted FCF guidance $160M-$180M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1639691/000163969126000031/0001639691-26-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1639691/000163969126000031/livn-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001639691-26-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer